Cyril Konto

3.1k total citations
28 papers, 465 citations indexed

About

Cyril Konto is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Cyril Konto has authored 28 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Immunology. Recurrent topics in Cyril Konto's work include CAR-T cell therapy research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Multiple Myeloma Research and Treatments (8 papers). Cyril Konto is often cited by papers focused on CAR-T cell therapy research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Multiple Myeloma Research and Treatments (8 papers). Cyril Konto collaborates with scholars based in United States, Belgium and France. Cyril Konto's co-authors include Michele Maio, Célèste Lebbé, Omid Hamid, Jedd D. Wolchok, Jeffrey S. Weber, M. Brent McHenry, Alessandro Testori, Bart Neyns, Steven O’Day and Kaan Harmankaya and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Cyril Konto

25 papers receiving 453 citations

Peers

Countries citing papers authored by Cyril Konto

Since Specialization

Citations

This map shows the geographic impact of Cyril Konto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyril Konto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyril Konto more than expected).

Fields of papers citing papers by Cyril Konto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyril Konto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyril Konto. The network helps show where Cyril Konto may publish in the future.

Co-authorship network of co-authors of Cyril Konto

This figure shows the co-authorship network connecting the top 25 collaborators of Cyril Konto. A scholar is included among the top collaborators of Cyril Konto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyril Konto. Cyril Konto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM) 2025 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), Hang Quach, Amit Khot, Bradley Augustson, Hanlon Sia, Nicole Wong Doo, David Levitz, Eben I. Lichtman, Michaela Liedtke, (unknown), Beata Holkova, (unknown), Lida Pacaud, (unknown), Maria Pihlgren, Mario Perro, Cyril Konto	0
2	Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients 2025 ·Cancer Research ·(unknown), Beata Holkova, Lida Pacaud, (unknown), (unknown), Maria Pihlgren, (unknown), Piet H. van der Graaf, Mario Perro, Cyril Konto	1
3	TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Hang Quach, Bradley Augustson, David Levitz, Hanlon Sia, Eben I. Lichtman, Nicole Wong Doo, Michaela Liedtke, (unknown), (unknown), (unknown), Cyril Konto, Lida Pacaud, Beata Holkova, Amit Khot	0
4	Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results. 2025 ·Journal of Clinical Oncology ·Eben I. Lichtman, Amit Khot, Bradley Augustson, David Levitz, Hanlon Sia, Nicole Wong Doo, Michaela Liedtke, (unknown), (unknown), (unknown), (unknown), Maria Pihlgren, Cyril Konto, Beata Holkova, Lida Pacaud, Hang Quach	1
5	First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Blood ·Hang Quach, Bradley Augustson, Hanlon Sia, Nishi Shah, Eben I. Lichtman, Michaela Liedtke, (unknown), (unknown), (unknown), Maria Pihlgren, Beata Holkova, Cyril Konto, Lida Pacaud, Amit Khot	2
6	Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma 2024 ·Blood ·Binod Dhakal, Hang Quach, (unknown), Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, (unknown), (unknown), (unknown), (unknown), Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian	1
7	Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis 2023 ·SHILAP Revista de lepidopterología ·Barbara Rewerska, Lawrence Sher, Sady Alpizar, (unknown), Grażyna Pulka, Neelufar Mozaffarian, Yacine Salhi, (unknown), (unknown), Girish Gudi, (unknown), (unknown), (unknown), (unknown), Riccardo Turrini, Marie‐Agnès Doucey, (unknown), Cyril Konto, (unknown)	26
8	Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) 2023 ·Blood ·Dickran Kazandjian, Hang Quach, Hanlon Sia, (unknown), Andrew Spencer, Mark A. Schroeder, Binod Dhakal, Tara Cochrane, Jeffrey A. Zonder, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Stefano Sammicheli, (unknown), Cyril Konto, Lida Pacaud, Peter Tan	5
9	P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES 2022 ·HemaSphere ·Camille Grandclément, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Girish Gudi, (unknown), (unknown), Roberto Giovannini, (unknown), Eric J. Feldman, Cyril Konto, (unknown), (unknown), (unknown)	1
10	First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. 2020 ·Journal of Clinical Oncology ·Sattva S. Neelapu, Javier Muñoz, Frederick L. Locke, David B. Miklos, Robert J. Brown, Jennifer McDevitt, Armen Mardiros, Eren Demirhan, Cyril Konto, Michael Tees	38
11	A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies 2016 ·Annals of Oncology ·Adi Diab, Anthony B. El-Khoueiry, Ferry A.L.M. Eskens, Willeke Ros, John A. Thompson, Cyril Konto, (unknown), Tenshang Joh, Kuo‐Wei Liao, Bishu Ganguly, Omid Hamid	12
12	First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. 2016 ·Journal of Clinical Oncology ·Omid Hamid, John A. Thompson, Adi Diab, Willeke Ros, Ferry A.L.M. Eskens, (unknown), Cyril Konto, Hua Long, (unknown), Bishu Ganguly, Catherine Fleener, Susan Pleasic‐Williams, Pamela D. Garzone, Premal H. Patel, Tenshang Joh, Dimitry S.A. Nuyten, Anthony B. El-Khoueiry	22
13	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies 2014 ·Annals of Oncology ·Célèste Lebbé, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Omid Hamid, Steven O’Day, Cyril Konto, (unknown), M. Brent McHenry, Jedd D. Wolchok	118
14	Efficacy, Safety, and Quality of Life (Qol) Data from the Eortc 18071 Phase III Trial of Ipilimumab (Ipi) Versus Placebo After Complete Resection of Stage III Melanoma 2014 ·Annals of Oncology ·Alexander Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Ravichandra Karra Gurunath, Veerle de Pril, Stefan Suciu, Alessandro Testori	4
15	CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM). 2013 ·Journal of Clinical Oncology ·F. Stephen Hodi, Asim Amin, Yvonne M. Saenger, Gregory Pennock, Troy H. Guthrie, April K.S. Salama, Lawrence E. Flaherty, Henry Koon, David H. Lawson, Montaser Shaheen, Ágnes Balogh, Cyril Konto, Steven O’Day	3
16	The cost of unresectable stage III or stage IV melanoma in Italy 2012 ·Journal of Experimental & Clinical Cancer Research ·Michele Maio, Paolo A. Ascierto, Alessandro Testori, Ruggero Ridolfi, Emilio Bajetta, Paola Queirolo, Michele Guida, Antonella Romanini, Vanna Chiarion‐Sileni, Jacopo Pigozzo, Anna Maria Di Giacomo, (unknown), (unknown), (unknown), Cyril Konto, Carlo Lucioni	26
17	Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study) 2012 ·European Journal of Cancer ·Karissa Johnston, Adrian R. Levy, Paul Lorigan, Michele Maio, Célèste Lebbé, Mark R. Middleton, Alessandro Testori, C. Bédane, Cyril Konto, (unknown), (unknown), (unknown)	36
18	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study) 2012 ·European Journal of Cancer ·Célèste Lebbé, Paul Lorigan, Paolo A. Ascierto, Alessandro Testori, C. Bédane, Michael Middleton, (unknown), Cyril Konto, (unknown), Michele Maio	23
19	CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. 2012 ·Journal of Clinical Oncology ·Antoni Ribas, F. Stephen Hodi, John F. Kurland, Vafa Shahabi, Stephen Francis, Cyril Konto, Andrew K. Joe, (unknown), Jedd D. Wolchok	12
20	Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. 2012 ·Journal of Clinical Oncology ·Jean‐François Baurain, Michael Smylie, Paolo A. Ascierto, Laslo Roman, Stephen Houston, Cyril Konto, Kevin M. Chin, Tai‐Tsang Chen, Stephen Francis, Jedd D. Wolchok	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact